Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-VII: Sirolimus-eluting (Ultimaster) vs. Everolimus-Eluting Stents (Xience)

Asan Medical Center0 个研究点目标入组 400 人开始时间: 待定最近更新: 2020年4月21日

试验速览

暂无简介。

•The patient must be at least 19 years of age.
•Significant native coronary artery stenosis (>50% by visual estimate) with lesion length of more than 25mm, which requiring at long stent placement without intervening normal segment.
•Patients with silent ischemia, stable or unstable angina pectoris, ad Non-ST-elevation myocardial infarction (NSTEMI)
•The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.

•Any contraindication to any of the following medications: aspirin, heparin, clopidogrel, stainless steel, contrast agents, sirolimus, or everolimus
•An elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs during the first 6 months post enrollment.
•Acute ST-segment-elevation MI or cardiogenic shock
•Terminal illness with life expectancy <1 year
•In-stent restenosis at target vessel (either bare metal stent or drug-eluting stent segment). However, non-target vessel ISR is permitted.
•Patients with EF<30%.
•Serum creatinine level = 2.0mg/dL or dependence on dialysis.
•Patients with left main stem stenosis (>50% by visual estimate)

发起方